Prognostic Value of<i>KIT</i>Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors
Samuel Singer(Memorial Sloan Kettering Cancer Center), Jonathan A. Fletcher(Harvard University), Marcia L. Lux(Brigham and Women's Hospital), Brian P. Rubin(Cleveland Clinic), Chang-Jie Chen(Brigham and Women's Hospital), George D. Demetri(Dana-Farber Cancer Institute), Christopher D.�M. Fletcher(Brigham and Women's Hospital)
Cited by 425
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k
High-throughput oncogene mutation profiling in human cancer
|Nature Genetics|2007|996